Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein

Molecular Therapy

Volumn 16, Issue 1, 2008, Pages 115-123

  Johansson, Henrik J ^a   El Andaloussi, Samir ^a   Holm, Tina ^a   Mäe, Maarja ^a   Jänes, Jaak ^b   Maimets, Toivo ^b   Langel, Ülo ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; ARF PROTEIN[1-22]; CELL PENETRATING PEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEOXYGLUCOSE; LACTATE DEHYDROGENASE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ONCOGENE; PROTEIN FUNCTION; PROTEIN TRANSPORT; SEQUENCE ANALYSIS;

EID: 37549056931     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300346     Document Type: Article

References (38)

1. Zindy, F, Eischen, CM, Randle, DH, Kamijo, T, Cleveland, JL, Sherr, CJ et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433.
2. Palmero, I, Pantoja, C and Serrano, M (1998). p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126.
3. Ameyar-Zazoua, M, Wisniewska, MB, Bakiri, L, Wagner, EF, Yaniv, M and Weitzman, JB (2005). AP-1 dimers regulate transcription of the p14/ p19ARF tumor suppressor gene. Oncogene 24: 2298-2306.
4. Sreeramaneni, R, Chaudhry, A, McMahon, M, Sherr,CJ and Inoue, K (2005). Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 25: 220-232.
5. Bates, S, Phillips, AC, Clark, PA, Stott F, Peters, G, Ludwig, RL et al. (1998). p14ARF links the tumour suppressors RB and p53. Nature 395: 124-125.
6. Qi, Y, Gregory, MA, Li, Z, Brousal, JF, West, K and Hann, SR (2004). p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717.
7. Eymin, B, Karayan, L, Seite, P, Brambilla, C, Brambilla, E, Larsen, CJ et al. (2001). Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20: 1033-1041.
8. Martelli, F, Hamilton, T, Silver, DP, Sharpless, NE, Bardeesy, N, Rokas, M et al. (2001). p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 98: 4455-4460.
9. Sugimoto, M, Kuo, ML, Roussel, MF and Sherr, CJ (2003). Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 11 415-424.
10. Bertwistle, D, Sugimoto, M and Sherr, CJ (2004). Physical and functional interactions of the Art tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24: 985-996.
11. EL-Andaloussi, S, Holm, T and Langel, Ü (2005). Cell-penetrating peptides: Mechanisms and applications. Curr Pharm Des 11: 3597-3611.
12. Fulda, S, Wick, W, Weller, M and Debatin, KM (2002). Smac agonists sensitize for Apo2L/TRAlL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815.
13. Plescia, J, Sa1z, W, Xia, F, Pennati, M, Zaffaroni, N, Daidone, MG et al. (2005). Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7: 457-468.
14. Sawada, M, Hayes, P and Matsuyama, S (2003). Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat Cell Biol 5: 352-357.
15. Kang, SH, Cho, MJ and Kole, R (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochemistry 37 6235-6239.
16. Oehlke, J, Scheller, A, Wiesner, B, Krause, E, Beyermann, M, Klauschenz, E et al. (1998). Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1414: 127-139.
17. Lohrum, MA, Ashcroft, M, Kubbutat, MH and Vousden, KH (2000). Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 10: 539-542.
18. Midgley, CA, Desterro, JM, Saville, MK, Howard, S, Sparks, A, Hay, RT et al. (2000). An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19: 2312-2323.
19. Bothner, B, Lewis, WS, DiGiammarino, EL, Weber, JD, Bothner, SJ and Kriwacki, RW (2001). Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 314: 263-277.
20. Kabir, J, Lobo, M and Zachary, I (2002). Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis. Biochem J 367: 145-155.
21. Kuo, ML, Duncavage, EJ, Mathew, R, den Besten, W, Pei, D, Naeve, D et al. (2003). Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 63: 1046-1053.
22. Weber, JD, Kuo, ML, Bothner, B, DiGiammarino, B, Kriwacki, RW, Roussel, MF et al. (2000). Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 20: 2517-2528.
23. DiGiammarino, EL, Filippov, I, Weber, JD, Bothner, B and Kriwacki, RW (2001). Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein. Biochemistry 40: 2379-2386.
24. Lundberg, M and Johansson, M (2001). Is VP22 nuclear homing an artifact? Nat Biotechnol 19: 713-714.
25. Richard, JP, Melikov, K, Vives, E, Ramos, C, Verbeure, B, Gait, MJ et al. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278: 585-590.
26. Tyagi, M, Rusnati, M, Presta, M and Giacca, M (2001). Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261.
27. Richard, JP, Melikov, K, Brooks, H, Prevot, P, Lebleu, B and Chemomordik, LV (2005). Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 280: 15300-15306.
28. Wadia, JS, Stan, RV and Dowdy, SF (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315.
29. Lundberg, P and Langel, O (2006). Uptake mechanisms of cell-penetrating peptides derived from the Alzheimer's disease associated gamma-secretase complex. Int J Pept Res Ther 12: 105-114.
30. Datta, A, Nag, A, Pan, W, Hay, N, Gartel, AL, Colamonici, O et al. (2004). Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 279: 36698-36707.
31. Hällbrink, M, Floren, A, Elmquist, A, Pooga, M, Bartfai, T and Langel, Ü (2001). Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 1515: 101-109.
32. Leduc, C, Claverie, P, Eymin, B, Col, E, Khochbin, S, Brambilla, E et al. (2006). p14(ARF) promotes RB accumulation through inhibition of its Tip60-dependent acetylation. Oncogene 25: 4147-4154.
33. Eymin, B, Claverie, P, Salon, C, Leduc, C, Col, E, Brambilla, E et al. (2006). p14ARF activates a Tip60-depenclent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 26: 4339-4350.
34. 2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation. Cell Cycle 5: 759-765.
35. 1 arrest function of ARF Mol Cell Biol 25: 8024-8036.
36. EL-Andaloussi, S, Johansson, HJ, Holm, T and Langel, Ü (2007). A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 15: 1820-1826.
37. Fischer, R, Mader, O, Jung, G and Brock, R (2003). Extending the applicability of carboxyfluorescein in solid-phase synthesis. Bioconjug Chem 14: 653-660.
38. EL-Andaloussi, S, Johansson, H, Magnusdottir, A, Järver, P, Lundberg, P and Langel, Ü (2005). TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J Control Release 110: 189-201.